米氮平

维基百科,自由的百科全书
跳转至: 导航搜索
米氮平
Mirtazapine 2D structure.svg
Mirtazapine-3D-ball-model.png
系统(IUPAC)命名名称
(±)-2-methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine
临床数据
商品名 瑞美隆(Remeron)
Drugs.com Monograph
MedlinePlus a697009
医疗法规
妊娠分级
  • AU: B3
  • US: C (不排除有风险的可能)
给药途径 口服
合法狀態
合法状态
药代动力学数据
生物利用度 50%[1][2][3][4]
蛋白结合度 85%[1][2][3][4]
代谢 肝脏 (CYP1A2, CYP2D6CYP3A4)[1][2][3][4][5]
生物半衰期 20–40小时[1][2][3][4]
排泄 尿液 (75%)[1]
粪便 (15%)[1][2][3][4]
识别信息
CAS注册号 61337-67-5 ✓
ATC代码 N06AX11
PubChem CID 4205
IUPHAR/BPS英语IUPHAR/BPS 7241
DrugBank DB00370 ✓
ChemSpider 4060 ✓
UNII A051Q2099Q ✗
KEGG D00563 ✓
ChEBI CHEBI:6950 ✗
ChEMBL英语ChEMBL CHEMBL654 ✓
其他名称 6-Azamianserin, Org 3770
化学信息
化学式 C17H19N3
摩尔质量 265.35 g/mol
物理性质
密度 1.22 g/cm3
熔点 114至116 °C(237至241 °F)
沸点 432 °C(810 °F)
水溶液 溶于甲醇氯仿 mg/mL (20 °C)
 ✗✓ (what is this?)英语Wikipedia:WikiProject_Chemicals/Chembox_validation  (verify)

米氮平(英语:Mirtazapine,商品名为樂活憂/瑞美隆(Remeron)[6],是一种去甲肾上腺素和特异性5-羟色胺能抗抑郁药 (NaSSA) [2] ,主要用来治疗抑郁症。米氮平也经常被用作抗焦虑药安眠药止吐药食欲促进剂。按分子结构分类时,米氮平被分类为四环类抗抑郁药(TeCA) ,并且为米安舍林的6-氮杂类似物。[6] 米氮平也是一种外消旋混合物,包含(R)- 和 (S)-异构体.[6]

医疗用途[编辑]

已批准的和适应症外使用[编辑]

米氮平主要用来治疗重度抑郁症和其他精神障碍。[7][8]

然而研究发现,米氮平对以下症状也有一定疗效,所以米氮平有时候也会被以适应症外使用的形式处方给以下症状的治疗:

研究性的[编辑]

有过文献报道的使用米氮平进行过实验性治疗的症状包括:

不良反应[编辑]

米氮平片的包装盒

不良反应[编辑]

信息源:[2][3][4][40][41][42]

十分常见 (发生几率≥10%) 
  • 口干 (25%)
  • 食欲增加 (17%)
  • 睡意 (54%), 镇静, 嗜睡
  • 体重增加(体重增加超过7%的情况仅常见于儿科)
常见 (1%≤ 几率 <10%) 
少见 (0.1%≤ 几率 <1%)
罕见 (几率 <0.1%)
频率未知

引用[编辑]

  1. ^ 1.0 1.1 1.2 1.3 1.4 1.5 Timmer, CJ; Sitsen, JM; Delbressine, LP. Clinical pharmacokinetics of mirtazapine. Clinical Pharmacokinetics. June 2000, 38 (6): 461–74. PMID 10885584. doi:10.2165/00003088-200038060-00001. 
  2. ^ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 REMERON (mirtazapine) tablet, film coated [Organon Pharmaceuticals USA]. DailyMed. Organon Pharmaceuticals USA. October 2012 [24 October 2013]. 
  3. ^ 3.0 3.1 3.2 3.3 3.4 3.5 Axit Mirtazapine PRODUCT INFORMATION. TGA eBusiness Services. alphapharm. 25 October 2011 [15 October 2013]. 
  4. ^ 4.0 4.1 4.2 4.3 4.4 4.5 Mirtazapine 30 mg Tablets - Summary of Product Characteristics (PDF). electronic Medicines Compendium. Sandoz Limited. 20 March 2013 [24 October 2013]. 
  5. ^ 5.0 5.1 Anttila, SA; Leinonen, EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Reviews. 2001, 7 (3): 249–64. PMID 11607047. doi:10.1111/j.1527-3458.2001.tb00198.x. 
  6. ^ 6.0 6.1 6.2 Brayfield, A (编). Mirtazapine. Martindale: The Complete Drug Reference (The Royal Pharmaceutical Society of Great Britain). 30 January 2013 [3 November 2013]. 
  7. ^ Gorman, JM. Mirtazapine: clinical overview. J Clin Psychiatry. 1999,. 60 Suppl 17: 9–13; discussion 46–8. PMID 10446735. 
  8. ^ Benjamin, S; Doraiswamy, PM. Review of the use of mirtazapine in the treatment of depression. Expert Opinion on Pharmacotherapy. July 2011, 12 (10): 1623–32. PMID 21644844. doi:10.1517/14656566.2011.585459. 
  9. ^ Goodnick, PJ; Puig, A; DeVane, CL; Freund, BV. Mirtazapine in major depression with comorbid generalized anxiety disorder. J Clin Psychiatry. July 1999, 60 (7): 446–8. PMID 10453798. doi:10.4088/JCP.v60n0705. 
  10. ^ 10.0 10.1 10.2 10.3 Croom, KF; Perry, CM; Plosker, GL. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs. 2009, 23 (5): 427–52. PMID 19453203. doi:10.2165/00023210-200923050-00006. 
  11. ^ Muehlbacher, M; Nickel, MK; Nickel, C; 等. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology. December 2005, 25 (6): 580–3. PMID 16282842. doi:10.1097/01.jcp.0000186871.04984.8d. 
  12. ^ Koran, LM; Quirk, T; Lorberbaum, JP; Elliott, M. Mirtazapine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol. October 2001, 21 (5): 537–9. PMID 11593084. doi:10.1097/00004714-200110000-00016. [不可靠的醫學來源?]
  13. ^ Carpenter, LL; Leon, Z; Yasmin, S; Price, LH. Clinical experience with mirtazapine in the treatment of panic disorder. Ann Clin Psychiatry. June 1999, 11 (2): 81–6. PMID 10440525. doi:10.3109/10401239909147053. [不可靠的醫學來源?]
  14. ^ Carli, V; Sarchiapone, M; Camardese, G; Romano, L; DeRisio, S. Mirtazapine in the treatment of panic disorder. Arch. Gen. Psychiatry. July 2002, 59 (7): 661–2. PMID 12090820. doi:10.1001/archpsyc.59.7.661. [不可靠的醫學來源?]
  15. ^ Landowski, J. [Mirtazapine--an antidepressant]. Psychiatria Polska. 2002, 36 (6 Suppl): 125–30. PMID 12647431 (Polish). 
  16. ^ Chinuck, RS; Fortnum, H; Baldwin, DR. Appetite stimulants in cystic fibrosis: a systematic review. Journal of Human Nutrition and Dietetics : the Official Journal of the British Dietetic Association. December 2007, 20 (6): 526–37. PMID 18001374. doi:10.1111/j.1365-277X.2007.00824.x. 
  17. ^ Davis, MP; Khawam, E; Pozuelo, L; Lagman, R. Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. A World Health Organization project. Expert Review of Anticancer Therapy. August 2002, 2 (4): 365–76. PMID 12647979. doi:10.1586/14737140.2.4.365. 
  18. ^ Hartmann, PM. Mirtazapine: a newer antidepressant. Am Fam Physician. January 1999, 59 (1): 159–61. PMID 9917581. 
  19. ^ Jindal, RD. Insomnia in patients with depression: some pathophysiological and treatment considerations. CNS Drugs. 2009, 23 (4): 309–29. PMID 19374460. doi:10.2165/00023210-200923040-00004. 
  20. ^ Nutt, DJ. Tolerability and safety aspects of mirtazapine. Human Psychopharmacology. June 2002,. 17 Suppl 1: S37–41. PMID 12404669. doi:10.1002/hup.388. 
  21. ^ 21.0 21.1 Li, TC; Shiah, IS; Sun, CJ; Tzang, RF; Huang, KC; Lee, WK. Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature. The Journal of ECT. June 2011, 27 (2): 165–7. PMID 21602639. doi:10.1097/YCT.0b013e3181e63346. 
  22. ^ Kast, RE; Foley, KF. Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care (Engl). July 2007, 16 (4): 351–4. PMID 17587360. doi:10.1111/j.1365-2354.2006.00760.x. 
  23. ^ Twycross, R; Greaves, MW; Handwerker, H; 等. Itch: scratching more than the surface. QJM : Monthly Journal of the Association of Physicians. January 2003, 96 (1): 7–26. PMID 12509645. doi:10.1093/qjmed/hcg002. 
  24. ^ Greaves, MW. Itch in systemic disease: therapeutic options. Dermatologic Therapy. 2005, 18 (4): 323–7. PMID 16297004. doi:10.1111/j.1529-8019.2005.00036.x. 
  25. ^ Colombo, B; Annovazzi, PO; Comi, G. Therapy of primary headaches: the role of antidepressants. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. October 2004,. 25 Suppl 3: S171–5. PMID 15549531. doi:10.1007/s10072-004-0280-x. 
  26. ^ Tajti, J; Almási, J. [Effects of mirtazapine in patients with chronic tension-type headache. Literature review]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakológiai Egyesület Lapja = Official Journal of the Hungarian Association of Psychopharmacology. June 2006, 8 (2): 67–72. PMID 17073214 (Hungarian). 
  27. ^ Kohler, M; Bloch, KE; Stradling, JR. Pharmacological approaches to the treatment of obstructive sleep apnoea. Expert Opinion on Investigational Drugs. May 2009, 18 (5): 647–56. PMID 19388881. doi:10.1517/13543780902877674. 
  28. ^ Marshall, NS; Yee, BJ; Desai, AV; Buchanan, PR; Wong, KK; Crompton, R; Melehan, KL; Zack, N; Rao, SG; Gendreau, RM; Kranzler, J; Grunstein, RR. Two randomized placebo-controlled trials to evaluate the efficacy and tolerability of mirtazapine for the treatment of obstructive sleep apnea. Sleep. June 2008, 31 (6): 824–31. PMC 2442407. PMID 18548827. 
  29. ^ Masi, G. Pharmacotherapy of pervasive developmental disorders in children and adolescents. CNS Drugs. 2004, 18 (14): 1031–52. PMID 15584771. doi:10.2165/00023210-200418140-00006. 
  30. ^ Marek, GJ; Carpenter, LL; McDougle, CJ; Price, LH. Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. February 2003, 28 (2): 402–12. PMID 12589395. doi:10.1038/sj.npp.1300057. 
  31. ^ Posey, DJ; Guenin, KD; Kohn, AE; Swiezy, NB; McDougle, CJ. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2001, 11 (3): 267–77. PMID 11642476. doi:10.1089/10445460152595586. 
  32. ^ Coskun, M; Karakoc, S; Kircelli, F; Mukaddes, NM. Effectiveness of mirtazapine in the treatment of inappropriate sexual behaviors in individuals with autistic disorder. J Child Adolesc Psychopharmacol. April 2009, 19 (2): 203–6. PMID 19364298. doi:10.1089/cap.2008.020. 
  33. ^ Kumar, R; Sachdev, PS. Akathisia and second-generation antipsychotic drugs. Current Opinion in Psychiatry. May 2009, 22 (3): 293–99. PMID 19378382. doi:10.1097/YCO.0b013e32832a16da. 
  34. ^ Hieber, R; Dellenbaugh, T; Nelson, LA. Role of mirtazapine in the treatment of antipsychotic-induced akathisia. Annals of Pharmacotherapy. June 2008, 42 (6): 841–6. PMID 18460588. doi:10.1345/aph.1K672. 
  35. ^ Graves, SM; Rafeyan, R; Watts, J; Napier, TC. Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: evidence from the bench and the bedside. Pharmacology & Therapeutics. December 2012, 136 (3): 343–353. PMC 3483434. PMID 22960395. doi:10.1016/j.pharmthera.2012.08.013. 
  36. ^ Ritsner, MS. Polypharmacy in Psychiatry Practice, Volume I. Springer Science+Business Media Dordrecht. 2013. ISBN 9789400758056. 
  37. ^ Vidal, C; Reese, C; Fischer, BA; Chiapelli, J; Himelhoch, S. Meta-Analysis of Efficacy of Mirtazapine as an Adjunctive Treatment of Negative Symptoms in Schizophrenia. Clinical Schizophrenia & Related Psychoses (Walsh Medical Media). March 2013: 1–24. ISSN 1935-1232. PMID 23491969. doi:10.3371/CSRP.VIRE.030813. 
  38. ^ Tagai, K; Nagata, T; Shinagawa, S; Tsuno, N; Ozone, M; Nakayama, K. Mirtazapine improves visual hallucinations in Parkinson's disease: a case report. Psychogeriatrics. June 2013, 13 (2): 103–107. PMID 23909968. doi:10.1111/j.1479-8301.2012.00432.x. 
  39. ^ Taylor, D; Paton, C; Shitij, K. The Maudsley prescribing guidelines in psychiatry. West Sussex: Wiley-Blackwell. 2012. ISBN 978-0-470-97948-8. 
  40. ^ mirtazapine (Rx) - Remeron, Remeron SolTab. Medscape. WebMD. [24 October 2013]. 
  41. ^ Australian Medicines Handbook. Australian Medicines Handbook Pty Ltd. 2013. 
  42. ^ British National Formulary (BNF) 65th. Pharmaceutical Press. : 1120. ISBN 978-0857110848.